Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Forsight Vision4 Inc. is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are being reviewed by 2 distinct examiners, which ensures that each application is being evaluated independently. The prosecution is further divided across 2 distinct art units, indicating that the company's intellectual property spans different specialized areas within the biotechnology sector.
HAEJIN S PARK is the busiest examiner for this entity, currently overseeing 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, the workload is evenly split, with each examiner handling exactly one case. The involvement of 2 distinct art units for only 2 pending actions suggests that the company's current filings are technically diverse enough to require review by different administrative departments.
Practitioners should be aware that with 2 distinct examiners and 2 distinct art units, there is no overlap in the personnel or the departments reviewing the 2 pending office actions. This requires a tailored approach for each application, as the tendencies of HAEJIN S PARK in one art unit may not be applicable to the other examiner in a different art unit. The current state of 1 pending action per examiner represents a balanced but fragmented prosecution environment.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEVY, BRANDON WILLIAM | 1 | 62.9% | +46.3% |
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
| TRUONG, QUANGLONG N | 1 | 78.6% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18187898 | POSTERIOR SEGMENT DRUG DELIVERY | PARK, HAEJIN S | 71d overdue |
| 17864120 | FLUID EXCHANGE APPARATUS FOR EXPANDABLE PORT DELIVERY SYSTEM AND METHODS OF USE | TRUONG, QUANGLONG N | 14d |
| 18823545 | IMPLANTABLE OCULAR DRUG DELIVERY DEVICES | LEVY, BRANDON WILLIAM | — |
| Art Unit | Apps |
|---|---|
| 3781 | 1 |
| 1614 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18823545 | IMPLANTABLE OCULAR DRUG DELIVERY DEVICES | LEVY, BRANDON WILLIAM | 3781 | §103Other | Final Rejection | — | Pending | Sep 03, 2024 |
| 18187898 | POSTERIOR SEGMENT DRUG DELIVERY | PARK, HAEJIN S | 1614 | §112DP | Final Rejection | 71d overdue | Pending | Mar 22, 2023 |
| 17864120 | FLUID EXCHANGE APPARATUS FOR EXPANDABLE PORT DELIVERY SYSTEM AND METHODS OF USE | TRUONG, QUANGLONG N | 1615 | DP | Non-Final OA | 14d | Pending | Jul 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialForsight Vision4 Inc. has 3 pending office actions as of November 2026, spread across 3 art units and 3 examiners.
Brandon William Levy has the most, with 1 of Forsight Vision4 Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.